172
Participants
Start Date
November 30, 2006
Primary Completion Date
September 30, 2011
Study Completion Date
March 31, 2012
Cladribine
Participants were administered with cladribine tablets orally as cumulative dose.
Placebo
Participants were administered with placebo orally.
Interferon-beta (IFN-beta)
Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
Research Site, Cullman
Research Site, Phoenix
Research Site, Scottsdale
Research Site, Los Angeles
Research Site, Boulder
Research Site, Fort Collins
Research Site, Tampa
Research Site, Atlanta
Research Site, Peoria
Research Site, Boston
Research Site, St Louis
Research Site, Newark
Research Site, Albuquerque
Research Site, Charlotte
Research Site, Winston-Salem
Research Site, Bethlehem
Research Site, Philadelphia
Research Site, Nashville
Research Site, Houston
Research Site, Round Rock
Research Site, Burlington
Research Site, Fidenza
Research Site, Milan
Research Site, Napoli
Research Site, Rome
Research Site, Arkhangelsk
Research Site, Kazan'
Research Site, Moscow
Research Site, Novosibirsk
Research Site, Saint Petersburg
Research Site, Samara
Research Site, Smolensk
Research Site, Alicante
Research site, Barcelona
Research Site, Bilbao
Research Site, Madrid
Research Site, Málaga
Research Site, Santiago
Research Site, Seville
EMD Serono Research & Development Institute, Inc.
INDUSTRY